Provided by Tiger Trade Technology Pte. Ltd.

Rallybio Corp.

4.75
+0.09882.12%
Pre-market: 4.51-0.2400-5.05%06:48 EST
Volume:82.75K
Turnover:395.37K
Market Cap:25.08M
PE:-1.88
High:5.37
Open:4.70
Low:4.41
Close:4.65
52wk High:7.20
52wk Low:1.76
Shares:5.28M
Float Shares:2.54M
Volume Ratio:3.51
T/O Rate:3.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.5283
EPS(LYR):-10.6143
ROE:-21.17%
ROA:-28.35%
PB:0.40
PE(LYR):-0.45

Loading ...

NASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM

Reuters
·
Feb 06

Rallybio Corp trading halted, news pending

TIPRANKS
·
Feb 06

BRIEF-Rallybio Announces Reverse Stock Split Of Common Stock

Reuters
·
Feb 04

Rallybio führt Aktiensplit im Verhältnis 1:8 durch

Reuters
·
Feb 04

Rallybio Corp - to Effect One-for-Eight Reverse Stock Split

THOMSON REUTERS
·
Feb 04

Rallybio Shareholders Approve Reverse Stock Split Amendment

TIPRANKS
·
Jan 30

Rallybio Corporation Held Special Shareholder Meeting

Reuters
·
Jan 30

Rallybio Terminates Phase 2 FNAIT Pregnancy Study: What Investors Need to Know

TIPRANKS
·
Jan 14

Rallybio’s Phase 2 FNAIT Prevention Study Reaches Completion: What Investors Should Watch Next

TIPRANKS
·
Jan 10

Rallybio Corporation Announces Date for Upcoming Special Stockholders Meeting

Reuters
·
Dec 24, 2025

Rallybio Corporation Reports Strong Q3 2025 Results

TIPRANKS
·
Nov 07, 2025

UPDATE: Rallybio Q3 Adj. EPS $(0.14) Beats $(0.21) Estimate, Sales $212.000K Beat $66.667K Estimate

Benzinga
·
Nov 06, 2025

Rallybio posts Q3 net income of $16 million

Reuters
·
Nov 06, 2025

BRIEF-Rallybio Q3 Net Income USD 16.016 Million

Reuters
·
Nov 06, 2025

Rallybio Corp - Cash Runway Extended Through 2027

THOMSON REUTERS
·
Nov 06, 2025

Rallybio Corp - Net Loss $0.36 per Common Share for Q3

THOMSON REUTERS
·
Nov 06, 2025

Rallybio’s RLYB116 Study: A Potential Game-Changer in Hematologic and Autoimmune Disease Treatment

TIPRANKS
·
Oct 28, 2025

Rallybio Completes Dosing of First Cohort in Rlyb116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

THOMSON REUTERS
·
Sep 25, 2025

Rallybio Corp: Data Readouts for Completed Study Expected in 4Q 2025

THOMSON REUTERS
·
Sep 25, 2025

Rallybio Receives $12.5 Million Equity Milestone Payment From Recursion for Advancement of REV102 Program

THOMSON REUTERS
·
Sep 03, 2025